Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 168

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 168
---
losure agreement. Our success relies on our ability to hire additional
employees, particularly on the local sales side. We believe there are numerous quality people to choose from throughout our area of targeted
expansion.

Subsidiaries

The Company has two wholly-owned subsidiary, Revium
Rx, Ltd. and LipoVation Ltd., each organized under the laws of the State of Israel.

Corporate Office

Our principal executive office is at 10 HaMenofim
Street Herzliya, Israel. Our main telephone number is 1 800 519-1687.

Legal Proceedings

There are no pending
legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or
beneficially of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or
has a material interest adverse to the Company. The Company’s property is not the subject of any pending legal proceedings.

<div align='center'>105

MANAGEMENT</div>

Executive Officers, Directors and Key Personnel

The following table sets forth information regarding our executive
officers and directors:

| Name              |     | Age |     | Position                                        |
| Amir Avraham      |     |  49 |     | Interim Chief Executive Officer                 |
| Inna Martin       |     |  49 |     | President, Chief Operating Officer and Director |
| Arie Gordashnikov |     |  42 |     | Chief Financial Officer and Treasurer           |
| Bernard Bartal    |     |  60 |     | Chairman, Director                              |
| Matti Munk        |     |  53 |     | Director                                        |
| Yoram Drucker     |     |  59 |     | Director                                        |

Amir Avraham, 49,was appointed Chief
Executive Officer on an interim basis, on May 22, 2205 following Mr. Akunis resignation from such position. Since February 2024,
Mr. Avraham has been a financial consultant with the Company, on a part time basis. Prior to his appointment as interim Chief Executive
at the Company, since February 2017 he has been General Manager and Chief Financial Officer at OCON Therapeutics, a global biotech company
drug device company, operating in Israel and Switzerland, where he led strategic planning and capital raises totaling over $15 million
while managing legal, financial, and global activities.